Molecular Pathways in Cancers

Edited by
March 2022
284 pages
  • ISBN978-3-0365-3682-8 (Hardback)
  • ISBN978-3-0365-3681-1 (PDF)

This book is a reprint of the Special Issue Molecular Pathways in Cancers that was published in

Biology & Life Sciences
Medicine & Pharmacology

This book includes some recent works providing the readers with novel relevant findings about the main signaling pathways that govern the molecular pathogenesis of some of the highest prevalent human tumors, which are the basis for developing alternative therapeutic strategies to improve patient outcomes.

  • Hardback
© 2022 by the authors; CC BY-NC-ND license
actin cytoskeletal reorganization; breast cancer; CD99 agonist; EGFR dimerization; endocytosis; FAK dephosphorylation; PTPN12; Rac1; RhoA; tripeptide; OMD; PRELP; tumor suppression gene; bladder cancer initiation; tight junction; partial EMT; tousled-like kinase (TLK); NIMA-related kinase 1 (NEK1); yes-associated protein 1 (YAP1); thioridazine (THD); MS-determined phosphopeptides; human immunodeficiency virus type 1; epithelial cells; carcinogenicity; oxidative stress; reactive oxygen species; gp120; Tat; Nef; matrix protein p17; reverse transcriptase; mitochondria; metastasis; OXPHOS; cancer; Warburg effect; cancer therapeutics; myeloproliferative neoplasms; signaling pathways; JAK2; CALR; MPL; TPOR; DUSP1; MAPK; Snail; prostate cancer; migration and invasion; patient survival; biomarkers; pBRD4; SET; PP2A; prognosis; triple negative breast cancer; breast cancer; resistance; anti-receptor therapy; trastuzumab; PI3K; mTOR; TAK-228; epigenetic; methylation; acetylation; non-coding RNA; small-cell lung cancer; triple-negative breast cancer; pancreatic ductal adenocarcinoma; glioblastoma; metastatic melanoma; advanced ovarian cancer; cancer; hepatocellular carcinoma; immune evasion; immunotherapy; immune checkpoint inhibitors; oncogenic signaling pathway; molecular targeted agents; genome; epigenome; tumor immune microenvironment; ovarian cancer; adaptive immunity; innate immunity; complement system; immunotherapy; cancer immunology; tumor microenvironment; splicing pathway; luminal breast cancer; BET inhibitors; n/a